Pulse Biosciences, Inc. (PLSE)

NCM – Real Time Price. Currency in USD

28.45

+0.95 (3.44%)

At close: Jun 26, 2026, 4:00 PM EDT

28.34

-0.11 (-0.38%)

After-hours: Jun 26, 2026, 7:19 PM EDT

10.06.2026

Pulse Biosciences, Inc. (PLSE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

10.06.2026

Pulse Biosciences, Inc. Announces Planned Redemption of Warrants

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that it intends to deliver an irrevocable notice of redemption, on or about June 10, 2026, to redeem the remaining common stock warrants issued by the Company as part of its July 3, 2024 rights offering. These outstanding common stock warrants (the “200% Warrants”), which were issued in the Com.

27.05.2026

Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced plans to participate in the upcoming Goldman Sachs 47th Annual Global Healthcare Conference in Miami Beach, FL. Pulse Biosciences' Management is scheduled to present on Wednesday, June 10, at 10:00 am ET. A live and recorded webcast of the fireside chat will be available on the “Events Calendar and Presentat.

26.05.2026

Here's Why Pulse Biosciences, Inc (PLSE) is a Great Momentum Stock to Buy

Does Pulse Biosciences, Inc (PLSE) have what it takes to be a top stock pick for momentum investors? Let's find out.

14.05.2026

Pulse Biosciences, Inc. (PLSE) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript

12.05.2026

ATM Equity Purchases by Pulse Biosciences' Co-Chairmen Total Approximately $13.3 Million

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced its Co-Chairmen of the Board, Robert Duggan and Chief Executive Officer Paul LaViolette, completed purchases of Pulse Biosciences' common stock through its at-the-market equity offering program (ATM) during the Company's designated trading window. In total, the Co-Chairmen acquired 675,233 shares of Pulse Bi.

08.05.2026

Pulse Biosciences Q1 Earnings Call Highlights

Pulse Biosciences NASDAQ: PLSE said it is sharpening its focus on its nanosecond pulsed field ablation platform for atrial fibrillation after reporting first-quarter 2026 results and highlighting new clinical data from its cardiac catheter program.

Videos

No Data

There is no data to display

Press releases

10.06.2026

Pulse Biosciences, Inc. Announces Planned Redemption of Warrants

12.05.2026

ATM Equity Purchases by Pulse Biosciences' Co-Chairmen Total Approximately $13.3 Million

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced its Co-Chairmen of the Board, Robert Duggan and Chief Executive Officer Paul LaViolette, completed purchases of Pulse Biosciences' common stock through its at-the-market equity offering program (ATM) during the Company's designated trading window. In total, the Co-Chairmen acquired 675,233 shares of Pulse Bi.

04.05.2026

Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced business updates and financial results for the first quarter ended March 31, 2026. Recent Business Highlights Endocardial Catheter AF Ablation Announced strategic prioritization of the nPulse Cardiac Catheter System following landmark clinical data, presented at AF Symposium, demonst.

25.04.2026

Pulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulse™ Cardiac Catheter System at Heart Rhythm 2026

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced late-breaking positive clinical data from its nPulse Cardiac Catheter System first-in-human feasibility study at the Heart Rhythm 2026 meeting. The late-breaking presentation included incremental participant follow up data. Building upon the previously reported data set presented at.

Pulse Biosciences, Inc. (PLSE)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Pulse Biosciences, Inc. (PLSE)

Pulse Biosciences, Inc. (PLSE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Pulse Biosciences, Inc. Announces Planned Redemption of Warrants

Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026

Here's Why Pulse Biosciences, Inc (PLSE) is a Great Momentum Stock to Buy

Pulse Biosciences, Inc. (PLSE) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript

ATM Equity Purchases by Pulse Biosciences' Co-Chairmen Total Approximately $13.3 Million

Pulse Biosciences Q1 Earnings Call Highlights

Videos

No Data

Press releases

Pulse Biosciences, Inc. Announces Planned Redemption of Warrants

ATM Equity Purchases by Pulse Biosciences' Co-Chairmen Total Approximately $13.3 Million

Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results

Pulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulse™ Cardiac Catheter System at Heart Rhythm 2026

Pulse Biosciences, Inc. (PLSE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Pulse Biosciences, Inc. Announces Planned Redemption of Warrants

Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026

Here's Why Pulse Biosciences, Inc (PLSE) is a Great Momentum Stock to Buy

Pulse Biosciences, Inc. (PLSE) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript

ATM Equity Purchases by Pulse Biosciences' Co-Chairmen Total Approximately $13.3 Million

Pulse Biosciences Q1 Earnings Call Highlights

Videos

No Data

Press releases

Pulse Biosciences, Inc. Announces Planned Redemption of Warrants

ATM Equity Purchases by Pulse Biosciences' Co-Chairmen Total Approximately $13.3 Million

Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results

Pulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulse™ Cardiac Catheter System at Heart Rhythm 2026

Search stocks

Pulse Biosciences, Inc. (PLSE)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Pulse Biosciences, Inc. (PLSE)

Pulse Biosciences, Inc. (PLSE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Pulse Biosciences, Inc. Announces Planned Redemption of Warrants

Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026

Here's Why Pulse Biosciences, Inc (PLSE) is a Great Momentum Stock to Buy

Pulse Biosciences, Inc. (PLSE) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript

ATM Equity Purchases by Pulse Biosciences' Co-Chairmen Total Approximately $13.3 Million

Pulse Biosciences Q1 Earnings Call Highlights

Videos

No Data

Press releases

Pulse Biosciences, Inc. Announces Planned Redemption of Warrants

ATM Equity Purchases by Pulse Biosciences' Co-Chairmen Total Approximately $13.3 Million

Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results

Pulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulse™ Cardiac Catheter System at Heart Rhythm 2026

Pulse Biosciences, Inc. (PLSE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Pulse Biosciences, Inc. Announces Planned Redemption of Warrants

Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026

Here's Why Pulse Biosciences, Inc (PLSE) is a Great Momentum Stock to Buy

Pulse Biosciences, Inc. (PLSE) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript

ATM Equity Purchases by Pulse Biosciences' Co-Chairmen Total Approximately $13.3 Million

Pulse Biosciences Q1 Earnings Call Highlights

Videos

No Data

Press releases

Pulse Biosciences, Inc. Announces Planned Redemption of Warrants

ATM Equity Purchases by Pulse Biosciences' Co-Chairmen Total Approximately $13.3 Million

Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results

Pulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulse™ Cardiac Catheter System at Heart Rhythm 2026